Dioscin Protects ANIT-Induced Intrahepatic Cholestasis Through Regulating Transporters, Apoptosis and Oxidative Stress

Overview

Journal Front Pharmacol

Date 2017 Mar 25

PMID 28337145

Citations 12

Authors

Hong Yao

Youwei Xu

Lianhong Yin

Xufeng Tao

Lina Xu

Yan Qi

Xu Han

Pengyuan Sun

Kexin Liu

Jinyong Peng

Affiliations

Soon will be listed here.

Abstract

Intrahepatic cholestasis, a clinical syndrome, is caused by excessive accumulation of bile acids in body and liver. Proper regulation of bile acids in liver cells is critical for liver injury. We previously reported the effects of dioscin against α-naphthylisothio- cyanate (ANIT)-induced cholestasis in rats. However, the pharmacological and mechanism data are limited. In our work, the animals of rats and mice, and Sandwich-cultured hepatocytes (SCHs) were caused by ANIT, and dioscin was used for the treatment. The results showed that dioscin markedly altered relative liver weights, restored ALT, AST, ALP, TBIL, GSH, GSH-Px, MDA, SOD levels, and rehabilitated ROS level and cell apoptosis. In mechanism study, dioscin not only significantly regulated the protein levels of Ntcp, OAT1, OCT1, Bsep and Mrp2 to accelerate bile acids excretion, but also regulated the expression levels of Bak, Bcl-xl, Bcl-2, Bax, Caspase 3 and Caspase 9 and to improve apoptosis. In addition, dioscin markedly inhibited PI3K/Akt pathway and up-regulated the levels of Nrf2, GCLc, GCLm, NQO1 and HO-1 against oxidative stress (OS) caused by bile acids. These results were further validated by inhibition of PI3K and Akt using the inhibitors of wortmannin and perifosine in SCHs. Our data showed that dioscin had good action against ANIT-caused intrahepatic cholestasis through regulating transporters, apoptosis and OS. This natural product can be considered as one active compound to treat intrahepatic cholestasis in the future.

Citing Articles

Novel insights into bexarotene's role in preventing cholestasis: mechanisms and implications.

Mohammed T, Zalzala M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40009169 DOI: 10.1007/s00210-025-03917-2.

Hepatoprotective Effects of Cilnidipine in Cholestatic Liver Disease: Role of FXR and NRF2 Signalling.

Mohammed T, Zalzala M J Exp Pharmacol. 2025; 17:93-105.

PMID: 39989470 PMC: 11844200. DOI: 10.2147/JEP.S504511.

Based on network pharmacology, the mechanism of Dioscin in alleviating renal tubular epithelial cell injury induced by calcium oxalate crystals was explored.

Liang H, Xu Y, Sun S, Chen Y, Wang W, Hao Z Urolithiasis. 2024; 53(1):3.

PMID: 39666011 DOI: 10.1007/s00240-024-01673-1.

The role of botanical triterpenoids and steroids in bile acid metabolism, transport, and signaling: Pharmacological and toxicological implications.

Luo Z, Zhou W, Xie T, Xu W, Shi C, Xiao Z Acta Pharm Sin B. 2024; 14(8):3385-3415.

PMID: 39220868 PMC: 11365449. DOI: 10.1016/j.apsb.2024.04.027.

The anti-cholestatic effects of Franch. alone and combined with (A. Jussieu) T. G. Hartley: dual effects on fecal metabolism and microbial diversity.

Han J, Wu P, Xu Z, Liu C, Chen Q, Zhang F Front Pharmacol. 2024; 15:1372527.

PMID: 38523644 PMC: 10957555. DOI: 10.3389/fphar.2024.1372527.

References

Li M, Han X, Yu B . Synthesis of monomethylated dioscin derivatives and their antitumor activities. Carbohydr Res. 2003; 338(2):117-21. DOI: 10.1016/s0008-6215(02)00443-3. View

Li R, Guo W, Fu Z, Ding G, Zou Y, Wang Z . Hepatoprotective action of Radix Paeoniae Rubra aqueous extract against CCl4-induced hepatic damage. Molecules. 2011; 16(10):8684-94. PMC: 6264168. DOI: 10.3390/molecules16108684. View

Ma X, Wang J, He X, Zhao Y, Wang J, Zhang P . Large dosage of chishao in formulae for cholestatic hepatitis: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2014; 2014:328152. PMC: 4060395. DOI: 10.1155/2014/328152. View

Chen Z, Zhu Y, Zhao Y, Ma X, Niu M, Wang J . Serum Metabolomic Profiling in a Rat Model Reveals Protective Function of Paeoniflorin Against ANIT Induced Cholestasis. Phytother Res. 2016; 30(4):654-62. DOI: 10.1002/ptr.5575. View

Perez M, Macias R, Duran C, Monte M, Gonzalez-Buitrago J, Marin J . Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J Hepatol. 2005; 43(2):324-32. DOI: 10.1016/j.jhep.2005.02.028. View

Tao X, Qi Y, Xu L, Yin L, Han X, Xu Y . Dioscin reduces ovariectomy-induced bone loss by enhancing osteoblastogenesis and inhibiting osteoclastogenesis. Pharmacol Res. 2016; 108:90-101. DOI: 10.1016/j.phrs.2016.05.003. View

Lu S . Regulation of glutathione synthesis. Mol Aspects Med. 2008; 30(1-2):42-59. PMC: 2704241. DOI: 10.1016/j.mam.2008.05.005. View

Tanaka Y, Chen C, Maher J, Klaassen C . Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. Transplantation. 2006; 82(2):258-66. DOI: 10.1097/01.tp.0000226243.69023.54. View

Cesaratto L, Vascotto C, Calligaris S, Tell G . The importance of redox state in liver damage. Ann Hepatol. 2004; 3(3):86-92. View

10.

Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall H, Zatloukal K . Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol. 2003; 38(6):717-27. DOI: 10.1016/s0168-8278(03)00096-5. View

11.

Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H . Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim Biophys Acta. 2001; 1511(1):7-16. DOI: 10.1016/s0005-2736(00)00355-2. View

12.

Xu W, Hellerbrand C, Kohler U, Bugnon P, Kan Y, Werner S . The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis. Lab Invest. 2008; 88(10):1068-78. DOI: 10.1038/labinvest.2008.75. View

13.

Roma M, Sanchez Pozzi E . Oxidative stress: a radical way to stop making bile. Ann Hepatol. 2008; 7(1):16-33. View

14.

Tanaka Y, Aleksunes L, Cui Y, Klaassen C . ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. Toxicol Sci. 2009; 108(2):247-57. PMC: 2664692. DOI: 10.1093/toxsci/kfp020. View

15.

Ohta Y, Kongo M, Sasaki E, Harada N . Change in hepatic antioxidant defense system with liver injury development in rats with a single alpha-naphthylisothiocyanate intoxication. Toxicology. 2000; 139(3):265-75. DOI: 10.1016/s0300-483x(99)00131-6. View

16.

Gonzalez-Sanchez E, Firrincieli D, Housset C, Chignard N . Nuclear receptors in acute and chronic cholestasis. Dig Dis. 2015; 33(3):357-66. DOI: 10.1159/000371688. View

17.

Kawai S, Arai T, Yokoyama Y, Nagino M, Nimura Y . Free oxygen radicals reduce bile flow in rats via an intracellular cyclic AMP-dependent mechanism. J Gastroenterol Hepatol. 2007; 22(3):429-35. DOI: 10.1111/j.1440-1746.2006.04486.x. View

18.

Okada K, Shoda J, Taguchi K, Maher J, Ishizaki K, Inoue Y . Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems. Biochem Biophys Res Commun. 2009; 389(3):431-6. DOI: 10.1016/j.bbrc.2009.08.156. View

19.

Yang H, Ramani K, Xia M, Ko K, Li T, Oh P . Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology. 2009; 49(6):1982-91. PMC: 2692579. DOI: 10.1002/hep.22908. View

20.

Yan G, Brouwer K, Pollack G, Wang M, Tidwell R, Hall J . Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models. J Pharmacol Exp Ther. 2011; 337(2):503-12. PMC: 3083101. DOI: 10.1124/jpet.110.177220. View